The purpose of this study is to demonstrate that the treatment does not cause any clinically significant effects that would put patients at risk.

Inclusion Criteria:

• Willing and able to provide written informed consent prior to participation in the clinical investigation
• Judged by the Investigator as suitable for participation in the study without safety concerns based on medical history, physical examination and laboratory results
• Age: 18-65 years of age.
• Gender: Male or female subjects.
• Negative urine drug screen (amphetamine, benzodiazepines, cocaine, marijuana, metamphetamine, morphine) at screening and Visit 2.
• Female subjects have to be post-menopausal for more than one year or use a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilisation, hormone implants, hormone injections, some intrauterine devices, abstinence, or vasectomised partner]). Oral contraceptives: combined pill (estrogen / progestin) and medium-dose progestin pill (for example desogestrel 75ug) are accepted only in combination with the partner using condoms.
• Willing and able to comply with all study procedures and restrictions

Exclusion Criteria:

• A diagnosis of asthma or chronic obstructive pulmonary disorder.

• Ongoing respiratory infection including the nasal cavity.

• Current malignancy of any kind.

• History of frequent nose bleeds or a condition that increases the risk of excessive bleeding.

• Pronounced anterior septal deviation or other significant nasal pathology.

• Known allergy to polyvinylchloride or medicinal liquid paraffin.

• Ongoing treatment with drugs indicated for respiratory or cardiac disorders.

• Any disease, condition (medical or surgical) including allergic, immunological and gastro-intestinal conditions and/or chronic medications which, in the opinion of the investigator, might compromise the study results, or would place the subject at increased risk.

• Vital signs with clinically significant deviations that would make the subject unsuitable for the study, as judged by the investigator.

• Evidence of significant cardiovascular disease defined by the following:

  1. New York Heart Association (NYHA) Class III or IV heart failure;
  2. Presence of symptomatic coronary artery disease or unstable angina;
  3. Persistent arrhythmia requiring chronic pharmacotherapy or implantable device;
  4. Clinically significant abnormalities seen on the screening electrocardiogram as assessed by the investigator;

• Clinically significant deviations in, hematology (including coagulation parameters aPTT and INR) variables, blood chemistry variables or urinalysis as assessed by the investigator.

• Positive screening test for HIV or hepatitis B or C

• Positive alcohol breath test at Visit 1 or at Visit 2.

• Non-smoker since at least six months at time of screening.

• Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.

• Previously treated with radiation on the face

• Previous radiation therapy to the head or neck regions

• Previously treated with an implantable stimulator or any implantable device in the head and / or neck

• Has a recent or repeated history of syncope.

• Has a recent or repeated history of seizures.

• Surgery within the past three months, determined by the PI to be clinically relevant.

• Strenuous exercise within 2 days of Visit 1 or Visit 2.

• Women who are pregnant or nursing.

• Female subjects: unwilling to use adequate contraceptive measures from the signing of the informed consent until end of the study at the follow-up visit.

• Received study drug in a clinical trial for an investigational drug within the previous 30 days, or 5 half-lives, whichever is longer.

• Blood donation or loss of whole blood exceeding 100 mL within 30 days from screening or plasma within 14 days from screening.

• Excessive intake of alcohol, defined as an average daily intake of greater than three units, or a maximum weekly intake of greater than 21 units ((three units equal 250 ml of 12% alcohol by unit wine).

• Concurrent condition or risk of non-compliance that, in the investigator's opinion, may affect the interpretation of performance or safety data or which otherwise contraindicates participation in a clinical investigation.